NCT06253234 — Beijing Tiantan Hospital cancer vaccine trial
Safety and Efficacy Study for DC Vaccine in Recurrent or Progressive High-grade Gliomas
Registry record
| Registry ID | NCT06253234 ↗ |
|---|---|
| Lead sponsor | Beijing Tiantan Hospital |
| Collaborators | ZhongSheng BioTech Inc. |
| Phase | Phase 1 |
| Status | Active Not Recruiting |
| Indication | WHO Grade III Gliomas, WHO Grade IV Gliomas |
| Enrollment | 12 participants (target) |
| Start date | 2024-02-02 |
| Primary completion | 2026-12-30 (est.) |
| Last registry update | 28 Sept 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT06253234), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT06253234?
NCT06253234 (Safety and Efficacy Study for DC Vaccine in Recurrent or Progressive High-grade Gliomas) is registered on ClinicalTrials.gov as Phase 1, sponsored by Beijing Tiantan Hospital.
Is NCT06253234 recruiting?
As of the 2026-09-28 registry update, NCT06253234 is listed as "Active Not Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT06253234?
The lead sponsor is Beijing Tiantan Hospital. Collaborators: ZhongSheng BioTech Inc..
What condition does NCT06253234 study?
The registered conditions are WHO Grade III Gliomas, WHO Grade IV Gliomas. Primary completion is listed as 2026-12-30 (estimated).
Are results available for NCT06253234?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT06253234.
Back to the full neoantigen vaccine trial tracker — 106 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.